Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines

被引:258
作者
Hollestelle, Antoinette [1 ]
Elstrodt, Fons [1 ]
Nagel, Jord H. A. [1 ]
Kallemeijn, Wouter W. [1 ]
Schutte, Mieke [1 ]
机构
[1] Erasmus MC, Dept Med Oncol, Josephine Nefkens Inst, NL-3000 DR Rotterdam, Netherlands
关键词
D O I
10.1158/1541-7786.MCR-06-0263
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Constitutive activation of the phosphatidylinositol-3-OH kinase (PI3K) and RAS signaling pathways are important events in tumor formation. This is illustrated by the frequent genetic alteration of several key players from these pathways in a wide variety of human cancers. Here, we report a detailed sequence analysis of the PTEN, PIK3CA, KRAS, HRAS, NRAS, and BRAF genes in a collection of 40 human breast cancer cell lines. We identified a surprisingly large proportion of cell lines with mutations in the PI3K or RAS pathways (54% and 25%, respectively), with mutants for each of the six genes. The PIK3CA, KRAS, and BRAF mutation spectra of the breast cancer cell lines were similar to those of colorectal cancers. Unlike in colorectal cancers, however, mutational activation of the PI3K pathway was mutually exclusive with mutational activation of the RAS pathway in all but 1 of 30 mutant breast cancer cell lines (P=0.001). These results suggest that there is a fine distinction between the signaling activators and downstream effectors of the oncogenic PI3K and RAS pathways in breast epithelium and those in other tissues.
引用
收藏
页码:195 / 201
页数:7
相关论文
共 49 条
[1]   Cancer-specific mutations in PIK3CA are oncogenic in vivo [J].
Bader, AG ;
Kang, SY ;
Vogt, PK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (05) :1475-1479
[2]   Oncogenic PI3K deregulates transcription and translation [J].
Bader, AG ;
Kang, SY ;
Zhao, L ;
Vogt, PK .
NATURE REVIEWS CANCER, 2005, 5 (12) :921-929
[3]  
Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO
[4]  
2-0
[5]  
BOS JL, 1989, CANCER RES, V49, P4682
[6]   Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis [J].
Cully, M ;
You, H ;
Levine, AJ ;
Mak, TW .
NATURE REVIEWS CANCER, 2006, 6 (03) :184-192
[7]   Distinct sets of genetic alterations in melanoma [J].
Curtin, JA ;
Fridlyand, J ;
Kageshita, T ;
Patel, HN ;
Busam, KJ ;
Kutzner, H ;
Cho, KH ;
Aiba, S ;
Bröcker, EB ;
LeBoit, PE ;
Pinkel, D ;
Bastian, BC .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2135-2147
[8]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[9]   BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants [J].
Elstrodt, F ;
Hollestelle, A ;
Nagel, JHA ;
Gorin, M ;
Wasielewski, M ;
van den Ouweland, A ;
Merajver, SD ;
Ethier, SP ;
Schutte, M .
CANCER RESEARCH, 2006, 66 (01) :41-45
[10]   Guilty as charged: B-RAF is a human oncogene [J].
Garnett, MJ ;
Marais, R .
CANCER CELL, 2004, 6 (04) :313-319